Connect Biopharma Holdings Limited (CNTB), a clinical-stage biopharmaceutical company, on Tuesday announced its first quarter financial results, and provided updates in the clinical trials for lead drug Rademikibart. Q1 2026: The company recorded a net loss of $19.39 million, or $0.34 per share...
Bristol Myers Squibb (BMY) and Hengrui Pharma (01276.HK) announced a strategic collaboration and license agreements to advance a portfolio of 13 early-stage programs in oncology, hematology and immunology. The partnership is designed to accelerate discovery and development of innovative medicines for the benefit of patients worldwide.
Eikon Therapeutics Inc. (EIKN), a late-stage biopharmaceutical company, on Monday released its first quarter financial results, and provided clinical updates. Q1 2026: The company recorded a net loss of $83 million in Q1 2026, while in the same period of 2025, the net loss was $74.5million. Research...
Pulse Biosciences, Inc. (PLSE), a developer of bioelectric medicine using its proprietary nPulse nanosecond pulsed field ablation (nsPFA) technology, announced that its Co-Chairman of the Board, Robert Duggan and CEO Paul LaViolette, have purchased company shares through its at-the-market equity offering program.
Oculis Holding AG (OCS), a clinical-stage biopharmaceutical company, on Monday reported its first-quarter financial results and provided pipeline highlights. The company specializes in developing therapies for treating ophthalmic, neuro-ophthalmic, and neurological diseases. Cash, cash equivalents,...
Coya Therapeutics (COYA) announced the FDA has granted Fast Track Designation for COYA 302, an investigational biologic combination therapy with a dual mechanism of action, for the treatment of amyotrophic lateral sclerosis. Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center,...
Fractyl Health, Inc. (GUTS) announced that regulators in the Netherlands have authorized the company to initiate a Phase 1/2 first-in-human study of RJVA-001, its lead candidate from the Rejuva Smart GLP-1 gene therapy platform. This marks the first adeno-associated virus (AAV)-based gene therapy to enter clinical development for type 2 diabetes.
SCYNEXIS, Inc. (SCYX), a clinical-stage biotechnology company focused on severe rare diseases, reported first-quarter 2026 financial results and highlighted progress across its pipeline including AMPK activator SCY-770 and antifungal candidates SCY-247.
Tonix Pharmaceutical Holding Corp (TNXP), a biopharmaceutical company, on Monday released its first-quarter financial results, provided business updates on its commercial products, and progress across its drug pipeline. The company is currently developing a diverse pipeline of drugs to treat diseases...
Sanara MedTech Inc. (SMTI), a medical technology company, on Monday released its first quarter financial results. The company specializes in the development and commercialization of technologies that improve clinical outcomes and reduce healthcare expenditures in the surgical market. Q1 2026: The...
The U.S. FDA launched a new initiative to advance drug repurposing, aiming to expand treatment options for patients with chronic and rare diseases where therapies remain limited. By encouraging the use of already approved medicines for new indications, the agency hopes to shorten development timelines and leverage existing safety data to bring therapies to patients faster.
aTyr Pharma, Inc. (ATYR) announced regulatory feedback and clinical plans for its lead candidate, Efzofitimod, in pulmonary sarcoidosis following a Type C meeting with the U.S. FDA.
Biomea Fusion Inc. (BMEA), a clinical-stage diabetes and obesity company, reported on Monday its first-quarter financial results and provided updates across its diabetes and obesity drug pipeline. Q1 2026: The company recorded a net loss of $12.41 million, or $0.17 per share, in Q1 2026, while...
SI-BONE, Inc. (SIBN) reported financial results for the first quarter ended March 31, 2026, showing double-digit revenue growth and improved profitability metrics compared to the prior year.
MacroGenics, Inc. (MGNX) has entered into a definitive agreement to sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd (6472.TW), with Bora paying $122.5 million upfront upon closing.
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.